Market by Clinical Application, Therapeutic Application, Biomarker Type, Analysis Platform, Analysis Purpose, Product, Industry Verticals, and Geography | Forecast 2021-2028
Triton Market Research’s detailed analysis of the global liquid biopsy market denotes that, based on revenue, the market is envisioned to grow at a CAGR of 18.54% during the forecasting years 2021-2028. In 2020, the market garnered $1179.1 million, and is projected to attain $4759.0 million by 2028.
Report scope can be customized per your requirements. Request For Customization
Liquid biopsy is a
non-invasive medical procedure that can detect the presence of molecular cancer
biomarkers in biological fluids. The derived test results help the medical
professional decide the further steps in the treatment of cancer patients.
The liquid biopsy technique
is based on capturing and analyzing the tumor-derived particles, including
nucleic acids, nucleosomes, exosomes, proteins, and cells. The two main
characteristics of malignant tumor cells are rapid cell division and
metastasis. Hence, finding traces of their existence in the body fluids is
possible with the help of analytical approaches with high sensitivity (NGS or
digital PCR). Thus, a liquid biopsy test enables non-invasive real-time cancer
screening and treatment monitoring.
Triton’s study aims to get an
overview of the liquid biopsy market in terms of various factors. Within this
report, the key insight and the market summary regarding the market have been
discussed. Besides, the Impact of COVID-19 on the liquid biopsy market;
Porter’s five forces model; market attractiveness matrix; initiatives
pertaining to liquid biopsy; legal, policy, & regulatory framework; vendor
scorecard; and key market strategies have been studied comprehensively.
Furthermore, market drivers
such as the high prevalence of cancer in the geriatric population, the growing
importance of liquid biopsy testing, and government initiatives are driving the
expansion of the studied market. Also, the advancement in technologies,
untapped diagnostic testing opportunities in developing nations, and consumer
demand for diagnostic centers are significant factors that the market can
leverage to accomplish the projected growth.
However, key market restraints, such as lack of reimbursement for liquid biopsy, disadvantages associated with compensation, shortage of skilled professionals, and elevated cost of the test, are impeding the global liquid biopsy market’s growth.
Major
geographies covered in the liquid biopsy
market by region are:
• North America: Canada and United States
• Europe: Russia, Spain, United Kingdom, Germany, France,
Italy, and Rest of Europe
• Asia-Pacific: Australia & New Zealand, Japan, India,
ASEAN countries, South Korea, China, and Rest of Asia-Pacific
• Latin America: Mexico, Brazil, and Rest of Latin America
• Middle East and Africa: United Arab Emirates, Turkey,
Saudi Arabia, South Africa, and Rest of Middle East & Africa
The global liquid biopsy market is segmented
into:
• Market by Clinical Application:
o Treatment
Monitoring
o Prognosis
and Reoccurrence Monitoring
o Treatment
Selection
o Diagnosis
and Screening
• Market by Therapeutic Application:
o Lung
Cancer
o Breast
Cancer
o Prostate
Cancer
o Colorectal
Cancer
o Melanoma
Cancer
o Other
Types of Cancer
o Non-Oncology
Application
• Market by Biomarker Type:
o Nucleic
Acid
o Protein
o Extracellular
Vesicles
o Cells
• Market by Analysis Platform:
o NGS
o Microarray
o PCR
o Proteomics
o Other
Analysis Platforms
• Market by Analysis Purpose:
o Early
Detection/Screening
o Therapy
Guidance
o Monitoring
o Diagnosis
• Market by Product:
o Circulating
Tumor DNA (CTDNA)
o Circulating
Tumor Cells (CTCS)
o Cell-Free
DNA (CFDNA)
o Extracellular
Vesicles and Others
• Market by Industry Verticals:
o Physicians’
Office Laboratories
o Hospitals
o Clinical
Diagnostic Laboratories
The reputed enterprises in
the liquid biopsy market include Bio-Rad Laboratories Inc, Qiagen NV, Illumina
Inc, F Hoffmann-La Roche, Agilent Technologies Inc, Adaptive Biotechnologies,
Menarini-Silicon Biosystems, Grail, Becton Dickinson and Company (BD), Myriad
Genetics Inc, Foundation Medicine, MDxHealth SA, Thermo Fisher Scientific Inc,
Angle Plc, Natera, Guardant Health Inc, Personal Genome Diagnostics, and
Biocept Inc.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT1. GLOBAL
LIQUID BIOPSY MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON LIQUID BIOPSY MARKET
2.2. KEY
INSIGHTS
2.3. PORTER’S
FIVE FORCES MODEL
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. COMPETITIVE
RIVALRY
2.4. INITIATIVES
PERTAINING TO LIQUID BIOPSY
2.5. LEGAL,
POLICY, & REGULATORY FRAMEWORK
2.6. MARKET
ATTRACTIVENESS INDEX
2.7. VENDOR
SCORECARD
2.8. KEY
MARKET STRATEGIES
2.8.1. CONTRACTS
AND PARTNERSHIP
2.8.2. BUSINESS
EXPANSION, ANNOUNCEMENTS, AND DIVESTITURES
2.8.3. ACQUISITIONS
& MERGERS
2.8.4. NEW
PRODUCT LAUNCHES
2.9.1. HIGH
PREVALENCE OF CANCER IN GERIATRIC POPULATION
2.9.2. GROWING
IMPORTANCE OF LIQUID BIOPSY TESTING
2.9.3. RISING
GOVERNMENT INITIATIVES
2.10. MARKET
RESTRAINTS
2.10.1. LACK
OF REIMBURSEMENT FOR LIQUID BIOPSY
2.10.2. DISADVANTAGES
ASSOCIATED WITH COMPENSATION
2.10.3. UNAVAILABILITY
OF SKILLED PROFESSIONALS
2.10.4. HIGH
COST OF LIQUID BIOPSY TEST
2.11. MARKET
OPPORTUNITIES
2.11.1. ADVANCEMENT
IN TECHNOLOGIES
2.11.2. UNTAPPED
DIAGNOSTIC TESTING OPPORTUNITIES IN DEVELOPING COUNTRIES
2.11.3. GROWING
DEMAND FOR DIAGNOSTIC CENTERS
3. GLOBAL
LIQUID BIOPSY MARKET - BY CLINICAL APPLICATION
3.1. TREATMENT
MONITORING
3.2. PROGNOSIS
AND REOCCURRENCE MONITORING
3.3. TREATMENT
SELECTION
3.4. DIAGNOSIS
AND SCREENING
4. GLOBAL
LIQUID BIOPSY MARKET - BY THERAPEUTIC APPLICATION
4.1. LUNG
CANCER
4.2. BREAST
CANCER
4.3. PROSTATE
CANCER
4.4. COLORECTAL
CANCER
4.5. MELANOMA
CANCER
4.6. OTHER
TYPES OF CANCER
4.7. NON-ONCOLOGY
APPLICATION
5. GLOBAL
LIQUID BIOPSY MARKET - BY BIOMARKER TYPE
5.1. NUCLEIC
ACID
5.2. PROTEIN
5.3. EXTRACELLULAR
VESICLES
5.4. CELLS
6. GLOBAL
LIQUID BIOPSY MARKET - BY ANALYSIS PLATFORM
6.1. NGS
6.2. MICROARRAY
6.3. PCR
6.4. PROTEOMICS
6.5. OTHER
ANALYSIS PLATFORMS
7. GLOBAL
LIQUID BIOPSY MARKET - BY ANALYSIS PURPOSE
7.1. EARLY
DETECTION/SCREENING
7.2. THERAPY
GUIDANCE
7.3. MONITORING
7.4. DIAGNOSIS
8. GLOBAL
LIQUID BIOPSY MARKET - BY PRODUCT
8.1. CIRCULATING
TUMOR DNA (CTDNA)
8.2. CIRCULATING
TUMOR CELLS (CTCS)
8.3. CELL-FREE
DNA (CFDNA)
8.4. EXTRACELLULAR
VESICLES AND OTHERS
9. GLOBAL
LIQUID BIOPSY MARKET - BY INDUSTRY VERTICALS
9.1. PHYSICIANS’
OFFICE LABORATORIES
9.2. HOSPITALS
9.3. CLINICAL
DIAGNOSTIC LABORATORIES
10. GLOBAL
LIQUID BIOPSY MARKET – REGIONAL OUTLOOK
10.1. NORTH
AMERICA
10.1.1. COUNTRY
ANALYSIS
10.1.1.1. UNITED
STATES
10.1.1.2. CANADA
10.2. EUROPE
10.2.1. COUNTRY
ANALYSIS
10.2.1.1. UNITED
KINGDOM
10.2.1.2. FRANCE
10.2.1.3. GERMANY
10.2.1.4. ITALY
10.2.1.5. RUSSIA
10.2.1.6. SPAIN
10.2.1.7. REST
OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. COUNTRY
ANALYSIS
10.3.1.1. JAPAN
10.3.1.2. CHINA
10.3.1.3. INDIA
10.3.1.4. SOUTH
KOREA
10.3.1.5. AUSTRALIA
& NEW ZEALAND
10.3.1.6. ASEAN
COUNTRIES
10.3.1.7. REST
OF ASIA-PACIFIC
10.4. LATIN
AMERICA
10.4.1. COUNTRY
ANALYSIS
10.4.1.1. BRAZIL
10.4.1.2. MEXICO
10.4.1.3. REST
OF LATIN AMERICA
10.5. MIDDLE
EAST AND AFRICA
10.5.1. COUNTRY
ANALYSIS
10.5.1.1. SAUDI
ARABIA
10.5.1.2. UNITED
ARAB EMIRATES
10.5.1.3. TURKEY
10.5.1.4. SOUTH
AFRICA
10.5.1.5. REST
OF MIDDLE EAST & AFRICA
11. COMPETITIVE
LANDSCAPE
11.1. ADAPTIVE
BIOTECHNOLOGIES
11.2. AGILENT
TECHNOLOGIES INC
11.3. ANGLE
PLC
11.4. BECTON
DICKINSON AND COMPANY (BD)
11.5. BIOCEPT
INC
11.6. BIO-RAD
LABORATORIES INC
11.7. F
HOFFMANN-LA ROCHE
11.8. FOUNDATION
MEDICINE
11.9. GRAIL
11.10. GUARDANT
HEALTH INC
11.11. ILLUMINA
INC
11.12. MDXHEALTH
SA
11.13. MENARINI-SILICON
BIOSYSTEMS
11.14. MYRIAD
GENETICS INC
11.15. NATERA
11.16. PERSONAL
GENOME DIAGNOSTICS
11.17. QIAGEN
NV
11.18. THERMO
FISHER SCIENTIFIC INC
12. RESEARCH
METHODOLOGY & SCOPE
12.1. RESEARCH
SCOPE & DELIVERABLES
12.1.1. OBJECTIVES
OF STUDY
12.1.2. SCOPE
OF STUDY
12.2. SOURCES
OF DATA
12.2.1. PRIMARY
DATA SOURCES
12.2.2. SECONDARY
DATA SOURCES
12.3. RESEARCH
METHODOLOGY
12.3.1. EVALUATION
OF PROPOSED MARKET
12.3.2. IDENTIFICATION
OF DATA SOURCES
12.3.3. ASSESSMENT
OF MARKET DETERMINANTS
12.3.4. DATA
COLLECTION
12.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1: GLOBAL LIQUID BIOPSY MARKET, BY REGION,
2021-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF CONTRACTS AND PARTNERSHIP
TABLE 4: LIST OF BUSINESS EXPANSIONS,
ANNOUNCEMENTS, AND DIVESTITURES
TABLE 5: LIST OF ACQUISITIONS & MERGERS
TABLE 6: LIST OF NEW PRODUCT LAUNCHES
TABLE 7: GOVERNMENT INITIATIVES PERTAINING TO
CANCER AND LIQUID BIOPSY IN SOME COUNTRIES
TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL
APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY
THERAPEUTIC APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER
TYPE, 2021-2028 (IN $ MILLION)
TABLE 11: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS
PLATFORM, 2021-2028 (IN $ MILLION)
TABLE 12: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS
PURPOSE, 2021-2028 (IN $ MILLION)
TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT,
2021-2028 (IN $ MILLION)
TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY INDUSTRY
VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY REGION,
2021-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA LIQUID BIOPSY MARKET, BY
COUNTRY, 2021-2028 (IN $ MILLION)
TABLE 17: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY,
2021-2028 (IN $ MILLION)
TABLE 18: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY
COUNTRY, 2021-2028 (IN $ MILLION)
TABLE 19: LATIN AMERICA LIQUID BIOPSY MARKET, BY
COUNTRY, 2021-2028 (IN $ MILLION)
TABLE 20: MIDDLE EAST AND AFRICA LIQUID BIOPSY
MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)
FIGURE 1: GLOBAL LIQUID BIOPSY
MARKET, BY REGION, 2021-2028 (IN $ MILLION)
FIGURE 2: GLOBAL LIQUID BIOPSY
MARKET, BY CLINICAL APPLICATION, 2020 & 2028 (IN %)
FIGURE 3: GLOBAL LIQUID BIOPSY
MARKET, BY TREATMENT MONITORING, 2021-2028 (IN $ MILLION)
FIGURE 4: GLOBAL LIQUID BIOPSY
MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2021-2028 (IN $ MILLION)
FIGURE 5: GLOBAL LIQUID BIOPSY
MARKET, BY TREATMENT SELECTION, 2021-2028 (IN $ MILLION)
FIGURE 6: GLOBAL LIQUID BIOPSY
MARKET, BY DIAGNOSIS AND SCREENING, 2021-2028 (IN $ MILLION)
FIGURE 7: GLOBAL LIQUID BIOPSY
MARKET, BY THERAPEUTIC APPLICATION, 2020 & 2028 (IN %)
FIGURE 8: GLOBAL LIQUID BIOPSY
MARKET, BY LUNG CANCER, 2021-2028 (IN $ MILLION)
FIGURE 9: GLOBAL LIQUID BIOPSY
MARKET, BY BREAST CANCER, 2021-2028 (IN $ MILLION)
FIGURE 10: GLOBAL LIQUID BIOPSY
MARKET, BY PROSTATE CANCER, 2021-2028 (IN $ MILLION)
FIGURE 11: GLOBAL LIQUID BIOPSY
MARKET, BY COLORECTAL CANCER, 2021-2028 (IN $ MILLION)
FIGURE 12: GLOBAL LIQUID BIOPSY
MARKET, BY MELANOMA CANCER, 2021-2028 (IN $ MILLION)
FIGURE 13: GLOBAL LIQUID BIOPSY
MARKET, BY OTHER TYPES OF CANCER, 2021-2028 (IN $ MILLION)
FIGURE 14: GLOBAL LIQUID BIOPSY
MARKET, BY NON-ONCOLOGY APPLICATION, 2021-2028 (IN $ MILLION)
FIGURE 15: GLOBAL LIQUID BIOPSY
MARKET, BY BIOMARKER TYPE, 2020 & 2028 (IN %)
FIGURE 16: GLOBAL LIQUID BIOPSY
MARKET, BY NUCLEIC ACID, 2021-2028 (IN $ MILLION)
FIGURE 17: GLOBAL LIQUID BIOPSY
MARKET, BY PROTEIN, 2021-2028 (IN $ MILLION)
FIGURE 18: GLOBAL LIQUID BIOPSY
MARKET, BY EXTRACELLULAR VESICLES, 2021-2028 (IN $ MILLION)
FIGURE 19: GLOBAL LIQUID BIOPSY
MARKET, BY CELLS, 2021-2028 (IN $ MILLION)
FIGURE 20: GLOBAL LIQUID BIOPSY
MARKET, BY ANALYSIS PLATFORM, 2020 & 2028 (IN %)
FIGURE 21: GLOBAL LIQUID BIOPSY
MARKET, BY NGS, 2021-2028 (IN $ MILLION)
FIGURE 22: GLOBAL LIQUID BIOPSY
MARKET, BY MICROARRAY, 2021-2028 (IN $ MILLION)
FIGURE 23: GLOBAL LIQUID BIOPSY
MARKET, BY PCR, 2021-2028 (IN $ MILLION)
FIGURE 24: GLOBAL LIQUID BIOPSY
MARKET, BY PROTEOMICS, 2021-2028 (IN $ MILLION)
FIGURE 25: GLOBAL LIQUID BIOPSY
MARKET, BY OTHER ANALYSIS PLATFORMS, 2021-2028 (IN $ MILLION)
FIGURE 26: GLOBAL LIQUID BIOPSY
MARKET, BY ANALYSIS PURPOSE, 2020 & 2028 (IN %)
FIGURE 27: GLOBAL LIQUID BIOPSY
MARKET, BY EARLY DETECTION/SCREENING, 2021-2028 (IN $ MILLION)
FIGURE 28: GLOBAL LIQUID BIOPSY
MARKET, BY THERAPY GUIDANCE, 2021-2028 (IN $ MILLION)
FIGURE 29: GLOBAL LIQUID BIOPSY
MARKET, BY MONITORING, 2021-2028 (IN $ MILLION)
FIGURE 30: GLOBAL LIQUID BIOPSY
MARKET, BY DIAGNOSIS, 2021-2028 (IN $ MILLION)
FIGURE 31: GLOBAL LIQUID BIOPSY
MARKET, BY PRODUCT, 2020 & 2028 (IN %)
FIGURE 32: GLOBAL LIQUID BIOPSY
MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2021-2028 (IN $ MILLION)
FIGURE 33: GLOBAL LIQUID BIOPSY
MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2021-2028 (IN $ MILLION)
FIGURE 34: GLOBAL LIQUID BIOPSY
MARKET, BY CELL-FREE DNA (CFDNA), 2021-2028 (IN $ MILLION)
FIGURE 35: GLOBAL LIQUID BIOPSY
MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2021-2028 (IN $ MILLION)
FIGURE 36: GLOBAL LIQUID BIOPSY
MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 37: GLOBAL LIQUID BIOPSY
MARKET, BY PHYSICIANS’ OFFICE LABORATORIES, 2021-2028 (IN $ MILLION)
FIGURE 38: GLOBAL LIQUID BIOPSY
MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)
FIGURE 39: GLOBAL LIQUID BIOPSY
MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2021-2028 (IN $ MILLION)
FIGURE 40: GLOBAL LIQUID BIOPSY
MARKET, BY REGION, 2020 & 2028 (IN %)
FIGURE 41: UNITED STATES LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 42: CANADA LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 43: UNITED KINGDOM LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 44: FRANCE LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 45: GERMANY LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 46: ITALY LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 47: RUSSIA LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 48: SPAIN LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 49: REST OF EUROPE LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 50: JAPAN LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 51: CHINA LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 52: INDIA LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 53: SOUTH KOREA LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 54: AUSTRALIA & NEW
ZEALAND LIQUID BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 55: ASEAN COUNTRIES LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 56: REST OF ASIA-PACIFIC
LIQUID BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 57: BRAZIL LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 58: MEXICO LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 59: REST OF LATIN AMERICA
LIQUID BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 60: SAUDI ARABIA LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 61: UNITED ARAB EMIRATES
LIQUID BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 62: TURKEY LIQUID BIOPSY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 63: SOUTH AFRICA LIQUID
BIOPSY MARKET 2021-2028 (IN $ MILLION)
FIGURE 64: REST OF MIDDLE EAST &
AFRICA LIQUID BIOPSY MARKET 2021-2028 (IN $ MILLION)